Iovance Biotherapeutics, Inc. (IOVA)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 1 | 164 | 264 | 325 | 403 |
| Operating profit | $m | -403 | -301 | ||||||
| Net profit | $m | -260 | -342 | -396 | -444 | -372 | -391 | -290 | -153 |
| EPS reported | $ | -1.09 | -0.70 | ||||||
| Operating cashflow per share | $ | -0.85 | -0.59 | ||||||
| Capex per share | $ | 0.09 | 0.07 | ||||||
| FCF per share | $ | -0.94 | -0.66 | ||||||
| Free cash flow | $m | -336 | -296 | ||||||
| Net debt | $m | -293 | -298 | ||||||
| Book value equity | $m | 699 | 736 | ||||||
| Book value per share | $ | 1.95 | 1.63 | ||||||
| Number of shares | m | 357.35 | 450.19 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 1.40 | 1.33 | ||||||
| P/S LTM | x | 3.70 | 3.00 | ||||||
| P/FCF LTM | x | -2.90 | -3.29 | ||||||
| EV/EBITDA LTM | x | -2.41 | -3.28 | ||||||
| EV/Sales LTM | x | 3.27 | 9.39 | ||||||
| Earnings Yield LTM | % | -40.08% | -9.21% | ||||||
| FCF Yield | % | -34.47% | -30.38% | ||||||
| Quality | |||||||||
| ROE | % | -55.97% | -40.51% | ||||||
| ROIC | % | -51.52% | -36.60% | ||||||
| Operating margin | % | -1.53% | -92.72% | ||||||
| Gross margin | % | +97.23% | +1.16% | ||||||
| FCF/Sales | % | -127.61% | -91.21% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +60.60% | +98.07% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -6.94 | -6.44 | ||||||
| Net Debt/EBITDA | x | 0.32 | 0.25 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | +0.41% | 0.00% | ||||||
| Net debt/Equity | x | -0.42 | -0.40 | ||||||
| Gross debt/equity | x | 0.07 | 0.06 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Iovance Biotherapeutics, Inc. (IOVA)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free